Biogen
BIIB
1,002 hedge funds and large institutions have $33.7B invested in Biogen in 2023 Q4 according to their latest regulatory filings, with 134 funds opening new positions, 288 increasing their positions, 375 reducing their positions, and 81 closing their positions.
65% more first-time investments, than exits
New positions opened: 134 | Existing positions closed: 81
29% more call options, than puts
Call options by funds: $645M | Put options by funds: $499M
4% more funds holding
Funds holding: 965 → 1,002 (+37)
3.62% more ownership
Funds ownership: 86.3% → 89.92% (+3.6%)
5% more capital invested
Capital invested by funds: $32.2B → $33.7B (+$1.56B)
23% less repeat investments, than reductions
Existing positions increased: 288 | Existing positions reduced: 375
27% less funds holding in top 10
Funds holding in top 10: 15 → 11 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$545M |
| 2 |
Morgan Stanley
New York
|
+$408M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$156M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$148M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$146M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$108M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$88.4M |
| 3 |
Renaissance Technologies
New York
|
-$80.5M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$66.2M |
| 5 |
D.E. Shaw & Co
New York
|
-$62.6M |
BIIB Hedge Fund Activity: Q4 2023 in Review
1,002 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2023, worth a combined $33.7B — up 4.8% from $32.2B a quarter earlier.
Buyers outnumbered sellers: 134 funds opened new BIIB positions and 81 closed out — a net gain of 53 holders — while 288 added to existing stakes and 375 trimmed.
The largest buyer was Vanguard Group, adding an estimated $545M. The largest seller was Samlyn Capital, exiting entirely with an estimated $108M sold.
- 1,002 institutional investors held Biogen (BIIB) as of Q4 2023, up from 965 in Q3 2023.
- Funds reported $33.7B of Biogen stock for Q4 2023, up 4.8% quarter-over-quarter.
- 134 funds opened new Biogen positions in Q4 2023 and 81 closed out, a net change of +53 holders.
- The largest Biogen buyer in Q4 2023 was Vanguard Group, an estimated $545M added.
- The largest Biogen seller in Q4 2023 was Samlyn Capital, an estimated $108M sold.
Based on aggregated 13F filings for Q4 2023.